![home](../images/home.gif) |
|
|
|
|
Slide |
083 |
Interventions for Tuberculosis Control and Elimination |
![next](../images/next.gif) |
Next |
![](slide_083_interventions.GIF) |
![previous](../images/previous.gif) |
Previous |
![beginning](../images/beginning.gif) |
First |
![last](../images/end.gif) |
Last |
In increasing number of countries adapted to switch directly to the most efficacious 6-month regimen containing rifampicin throughout as their first-line regimen. This is and was understandable under the ethical imperative that any patient should receive the most efficacious known regimen.
However, the approach has a serious drawback as it destroys the concept of a cascade of regimens unless the fall-back regimen was designed to cure multidrug-resistant tuberculosis.
It is apparent that patients failing on a rifampicin containing continuation phase in the first-line regimen cannot be cured with the standard retreatment regimen: the only effect is the potential to also acquire ethambutol resistance.
Countries not disposing of second-line drugs and an infrastructure to deliver them would thus have to put a fallback regimen for the treatment of multidrug-resistant tuberculosis at the disposal of all patients requiring it because of a bacteriological failure to the first line regimen. |
|
|
Go to top
Last update:
September 29, 2010